The Peptide Policy Waiting at the White House: What "Interim Access" Would — and Wouldn't — Change

Editorial update — October 22, 2026

When we covered the July PCAC vote, we closed with a piece of advice: watch the rulemaking docket, not the applause. The docket just moved. On October 14, 2026, the White House Office of Management and Budget received for review an FDA document titled “Interim Access Policy for Compounding Using Certain Peptides” — RIN 0910-ZD94, filed at the notice stage, with no legal deadline attached.

That is the entire public record. The text has not been published. Nobody outside the government knows which peptides it covers, what conditions it attaches, or when it would take effect. The Alliance for Pharmacy Compounding — the compounding industry’s own trade group — says exactly that: “we don’t yet know what the policy says, which peptides it covers, or what conditions FDA may attach to their compounding.”

What we can do is explain what a document with this title, at this stage, most plausibly is — and set it against a thing almost no coverage has put next to it: the same two months produced the most aggressive enforcement campaign the gray-market peptide trade has ever seen.

What was actually submitted

Under Executive Order 12866, significant regulatory actions go to OMB’s Office of Information and Regulatory Affairs before an agency may issue them. The reginfo.gov entry tells us four things: the title, the agency (HHS/FDA), the stage (“Notice” — not a proposed or final rule), and the date received. It is marked not economically significant.

The “notice” stage matters. Formally adding a peptide to the 503A bulk substances list — the thing the July advisory vote recommended for BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon — requires notice-and-comment rulemaking, a process that took three years the last time the agency ran it to completion for a batch of bulk substances (proposed 2016, finalized 2019). A “notice” is something lighter. Legal analysts across the board — Buchanan Ingersoll, Holland & Knight — read it the same way: an exercise of enforcement discretion, in which the FDA announces it does not intend to take action against state-licensed 503A pharmacies compounding certain peptides while the formal process grinds on.

The Washington Post reported on October 7 — a week before the OMB submission, citing unnamed sources — that the administration was preparing exactly this, and that BPC-157 was among the peptides covered. HHS Secretary Robert F. Kennedy Jr. has publicly backed broader peptide access since February. None of that reporting is confirmed by any published text.

What enforcement discretion is — and is not

If the policy emerges in the expected form, here is the honest version of what changes.

What it would do. Tell state-licensed compounding pharmacies that the FDA does not, for now, intend to pursue them for compounding the named peptides, likely under conditions. The Alliance for Pharmacy Compounding has asked for exactly this, proposing patient disclosures, serious-adverse-event reporting and data collection as the price of admission — though whether those conditions appear in the final text is unknown.

What it would not do. It would not approve anything. Every covered peptide would remain an unapproved drug. It would not add anything to the 503A bulks list — that still requires rulemaking. It would not establish safety or efficacy; the FDA’s own review scientists recommended against all seven peptides on exactly those grounds in June, and no new human trial has appeared since. It would not override state pharmacy and prescribing law. And — this is the part a policy built on discretion cannot escape — it could be withdrawn at any time, without rulemaking, by the same signature that created it. Holland & Knight’s October 16 client alert is blunt that a durable federal pathway is a 2027–2028 project at the earliest, and that a rule departing from the agency’s own scientific findings invites court challenge.

The other track: the crackdown nobody is putting in the same story

Read in isolation, the interim policy looks like the door swinging open. Read against the enforcement record of August through October, it looks like something narrower: the FDA sorting the market into one lane it is prepared to tolerate — licensed pharmacies, prescriptions, conditions — and everything else, which it is now hitting harder than at any point in this market’s history.

The record, in order:

• August 12 — Eli Lilly filed six federal lawsuits against sellers of its investigational drug retatrutide — “research use only” vendors, a med spa, a compounding pharmacy — and announced more than 200 referrals to the FDA, DOJ, state attorneys general and licensing boards.
• August 24 — the FDA issued five warning letters to online peptide vendors, dismantling the “research use only” fiction directly: sites that sell injectable peptides alongside bacteriostatic water and insulin syringes are, in the agency’s reading, selling unapproved new drugs for human use, whatever the label says.
• August–September — the FDA and CDC linked more than 25 illnesses in at least four states — including hospitalizations, one patient critically ill with shock and abnormal clotting — to compounded glutathione injections made with dietary-supplement-grade ingredient carrying elevated endotoxin levels. Three Texas pharmacies recalled product.
• September 18 — a warning letter against a compounder’s GLP-1 products with added B12 or niacinamide, which the agency called “essentially copies” of approved drugs — part of a broader squeeze that began with the April proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list.

The glutathione cluster deserves particular weight, because it is a preview of the exact failure mode an interim access policy would have to manage. Glutathione is legal to compound. The patients got it from licensed pharmacies, many on prescriptions. The harm came from ingredient quality — a supplement-grade powder that was never endotoxin-controlled for injection. “Compounded by a licensed pharmacy” is a statement about who made it, not about what’s in the vial. We made this point at length in our compounding safety review last year; 2026 keeps supplying the case studies.

What to watch

Three things, in order of information value:

1. The published text. OMB review of a non-economically-significant notice can conclude in weeks (there are also reports of a 50-deep HHS backlog). When the policy publishes, the details are the story: which peptides, which conditions, and whether the APC’s proposed guardrails — disclosures, adverse-event reporting, data collection — survived.
2. The second PCAC meeting, expected in early 2027, covering the next five: GHK-Cu, LL-37, Dihexa, Melanotan II and PEG-MGF. If the first meeting’s pattern holds — agency scientists against, committee in favor — the interim-policy question will be asked again for a group that includes a tanning peptide with a well-documented adverse-event record.
3. The formal rulemaking, which still has not begun. Everything until then is discretion, and discretion is weather.

The bottom line

A document at OMB is not a policy; a policy built on enforcement discretion is not approval; and approval is not evidence. The October 14 submission is the most concrete signal yet that the FDA intends to open a supervised lane for compounded peptides rather than let the gray market keep filling the demand — and the enforcement record of the past ninety days shows what happens to everyone standing outside that lane. But nothing about the science moved this month. The peptides in question still lack the controlled human trials the FDA’s own reviewers said they lack in June, and the one safety story 2026 has actually delivered — twenty-five people sickened by a legally compounded injectable — is an argument for exactly the kind of scrutiny the interim policy proposes to relax. When the text publishes, we’ll read it against the conditions, not the headlines.